HealthEquity (HQY) Could Be 14% Undervalued As HSA Market Access Expands
HealthEquity (HQY) has been drawing fresh attention after its recent share price move, with the stock roughly flat over the past week but posting a double-digit gain over the past month.
At around $103.05, HealthEquity’s recent 14.3% one-month share price return contrasts with a modest 3.6% total shareholder return over the past year. This points to momentum building more in the short term than over the longer stretch.
Scan how HealthEquity compares with other recently active healthcare names by running through a curated set of 29 resilient stocks with low risk scores.
HealthEquity has already logged a sharp one month move, so the real tension now is simple. Is most of the upside already in the rearview, or is the valuation still pointing to more room ahead?
Most Popular Narrative: 14% Undervalued
On the analyst consensus Narrative on Simply Wall St, HealthEquity’s fair value sits at about $119.33 against a last close of $103.05. This frames the recent rally as still leaving a valuation gap based on those forecasts and discount rate assumptions.
The recent regulatory expansion that allows direct primary care, pre-deductible telehealth and new ACA Bronze and catastrophic plan members to qualify for HSAs continues to enlarge HealthEquity’s addressable market. This can feed future HSA account and asset growth and support revenue.
See why 7 investors see HealthEquity as 14% undervalued.
Result: Fair Value of $119.33 (UNDERVALUED)
Still, the HealthEquity story can be knocked off course if employment softens and new HSA account openings slow, or if fee pressure keeps service revenue under strain.
Find out about the key risks to this HealthEquity narrative.
Another View On HealthEquity’s Valuation
There is a twist once you step away from fair value estimates and look at simple market ratios. HealthEquity trades on a P/E of 36x, which is above its own fair ratio of 27.1x and also higher than the broader US Healthcare sector at 25.3x.
Peer comparisons are less demanding, with similar companies around 37.6x, yet that still leaves a gap between today’s multiple and the fair ratio that the market could move toward. For anyone tracking HQY, that spread raises a straightforward question: Is this price reflecting quality or just leaving less room for error if sentiment cools?
For a closer look at how this valuation gap might matter in practice, walk through the detailed breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
That context, alongside the industry and peer comparison in the
Next Steps
Sentiment around HealthEquity has clear pros and cons, which is exactly why it helps to test the numbers yourself and move quickly while the data is fresh. If you want to see what is driving the optimism in more detail, start with the 3 key rewards.
Looking for more ideas beyond HealthEquity?
If you are serious about sharpening your next move, do not stop with one stock. Let a few targeted screens surface opportunities you might otherwise miss.
- Push for potential value gaps by scanning a curated set of 32 high quality undervalued stocks that pair stronger fundamentals with prices that may not fully reflect them yet.
- Prioritize staying power and sleep-better-at-night balance sheets by filtering for a list of solid balance sheet and fundamentals (23 results) that can handle rough patches without constant drama.
- Hunt for tomorrow’s standouts today with a focused 20 high quality undiscovered gems that highlights quality businesses before they attract wider attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com